<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Supreme</title>
	<atom:link href="http://www.tapanray.in/tag/supreme/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>When Patents, Patients and Prices Collide</title>
		<link>http://www.tapanray.in/when-patents-patients-and-prices-collide/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-patents-patients-and-prices-collide</link>
		<comments>http://www.tapanray.in/when-patents-patients-and-prices-collide/#comments</comments>
		<pubDate>Sun, 19 Oct 2025 12:39:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[atrophy]]></category>
		<category><![CDATA[Collide]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Evrysdi]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[muscular]]></category>
		<category><![CDATA[Natco Pharma]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Risdiplam]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[spinal]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10982</guid>
		<description><![CDATA[Supreme Court Clears Natco to Launch Low-Cost Version of Roche’s Spinal Drug in India: A Judgment That Redefines Access and Innovation in India’s Pharma Landscape. The Supreme Court of India has just recently refused to interfere with the Delhi High &#8230; <a href="http://www.tapanray.in/when-patents-patients-and-prices-collide/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-patents-patients-and-prices-collide/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid 2.0 Rampages India As Top Echelon Policy Makers Ignore Science</title>
		<link>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science</link>
		<comments>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/#comments</comments>
		<pubDate>Mon, 26 Apr 2021 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[appropriate]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[dilemmas]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[misgivings]]></category>
		<category><![CDATA[MIT]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[overwhelmed]]></category>
		<category><![CDATA[Oxygen]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[rampage]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[side-effects]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10482</guid>
		<description><![CDATA[‘India is in the endgame of COVID,’ announced the union health minister of India, just in the last month – March 08, 2021. Although, it was then clearly known to medical fraternity that today’s Covid vaccines won’t be magic bullets against rapidly &#8230; <a href="http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multifaceted Coronavirus Narrative Raises Multiple Questions</title>
		<link>http://www.tapanray.in/multifaceted-coronavirus-narrative-raises-multiple-questions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multifaceted-coronavirus-narrative-raises-multiple-questions</link>
		<comments>http://www.tapanray.in/multifaceted-coronavirus-narrative-raises-multiple-questions/#comments</comments>
		<pubDate>Mon, 06 Apr 2020 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[21 day]]></category>
		<category><![CDATA[attack]]></category>
		<category><![CDATA[battle gear]]></category>
		<category><![CDATA[cacophony]]></category>
		<category><![CDATA[CJI]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[Deadly]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[Gear]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[invisible]]></category>
		<category><![CDATA[laborers]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[microbe]]></category>
		<category><![CDATA[migrant]]></category>
		<category><![CDATA[Multifaceted]]></category>
		<category><![CDATA[Narrative. Raises. Multiple]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[paramedic]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[PPE]]></category>
		<category><![CDATA[protective]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Serbia]]></category>
		<category><![CDATA[showstoppers]]></category>
		<category><![CDATA[situation]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[violation]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[war]]></category>
		<category><![CDATA[workforce]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9960</guid>
		<description><![CDATA[Last night, amid the national lockdown, many people followed Prime Minister Modi’s video message, broadcasted on April 03 at 9 am for all, ‘to challenge the darkness of Coronavirus together &#8211; with a Diya, candle, torch or flashlight, at 9 pm for 9 &#8230; <a href="http://www.tapanray.in/multifaceted-coronavirus-narrative-raises-multiple-questions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multifaceted-coronavirus-narrative-raises-multiple-questions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Escalating Antibiotic Resistance, And Thwarting Ban Of Irrational FDCs</title>
		<link>http://www.tapanray.in/escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs</link>
		<comments>http://www.tapanray.in/escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs/#comments</comments>
		<pubDate>Sun, 20 Nov 2016 23:35:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[National Policy for Containment of Antimicrobial Resistance in India]]></category>
		<category><![CDATA[New Delhi metallo-β-lactamase]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resistance]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[thwarting]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7973</guid>
		<description><![CDATA[September 2016 ‘Fact Sheet’ of the World Health Organization (W.H.O) raised a red flag on fast increasing incidence of Antimicrobial Resistance (AMR). It poses a serious threat to global public health, more than ever before. Consequently, effective prevention and treatment &#8230; <a href="http://www.tapanray.in/escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?</title>
		<link>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/#comments</comments>
		<pubDate>Mon, 19 Oct 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AIOCD-AWACS]]></category>
		<category><![CDATA[apex]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[corollary]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crocin Advance]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health care UHC]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safeguard]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7183</guid>
		<description><![CDATA[The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a &#8230; <a href="http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Highest Billionaire Wealth Concentration, India Tops Malnutrition Chart in South Asia: &#8220;What Future Do You Want?&#8221;</title>
		<link>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want</link>
		<comments>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/#comments</comments>
		<pubDate>Mon, 26 Jan 2015 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amit]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Billionaire]]></category>
		<category><![CDATA[BJP]]></category>
		<category><![CDATA[Chart]]></category>
		<category><![CDATA[Concentration]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Davos]]></category>
		<category><![CDATA[demographic]]></category>
		<category><![CDATA[dividend]]></category>
		<category><![CDATA[Gates]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[highest]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequality]]></category>
		<category><![CDATA[Justice Louis Brandeis]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[oxfam]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Shah]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tops]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UNICEF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Wealth]]></category>
		<category><![CDATA[WEF]]></category>
		<category><![CDATA[What Future Do You Want]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6352</guid>
		<description><![CDATA[Two recent global research reports, though on different spheres, place India at the top of the respective blocks. However, the take away messages that the studies offer are indeed poles apart in qualitative terms and worth pondering over collectively. On &#8230; <a href="http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Outlook 2015: A Glimpse Of Some Drivers and Barriers</title>
		<link>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers</link>
		<comments>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/#comments</comments>
		<pubDate>Mon, 05 Jan 2015 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[exports]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Nadda]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6291</guid>
		<description><![CDATA[Looking ahead, the brand new year 2015 appears quite interesting to me both from the global and also from the local pharmaceutical industry perspective. In this article I shall try to give a glimpse of some of the important drivers &#8230; <a href="http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The New Government To Ponder: Is “Market Based Drug Pricing Policy” An ill Conceived One?</title>
		<link>http://www.tapanray.in/the-new-government-to-ponder-is-market-based-drug-pricing-policy-an-ill-conceived-one/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-new-government-to-ponder-is-market-based-drug-pricing-policy-an-ill-conceived-one</link>
		<comments>http://www.tapanray.in/the-new-government-to-ponder-is-market-based-drug-pricing-policy-an-ill-conceived-one/#comments</comments>
		<pubDate>Wed, 04 Jun 2014 07:22:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Ananth]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[ceiling]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[conceived]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ill]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Kumar]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[ponder]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5489</guid>
		<description><![CDATA[According to a recent media report, Mr. Ananth Kumar, the new minister of Chemicals and Fertilizers has recently made a statement, as follows: &#8220;&#8230; As far as branded medicines of multinational pharmaceutical companies are concerned, we will talk to all &#8230; <a href="http://www.tapanray.in/the-new-government-to-ponder-is-market-based-drug-pricing-policy-an-ill-conceived-one/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-new-government-to-ponder-is-market-based-drug-pricing-policy-an-ill-conceived-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Sun Pharma Sailing In The Same Boat As Ranbaxy?</title>
		<link>http://www.tapanray.in/is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy</link>
		<comments>http://www.tapanray.in/is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy/#comments</comments>
		<pubDate>Wed, 21 May 2014 07:57:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[boat]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[Chouhan]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sailing]]></category>
		<category><![CDATA[SEBI]]></category>
		<category><![CDATA[Sikri]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Vadodara]]></category>
		<category><![CDATA[Vod]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5420</guid>
		<description><![CDATA[A ‘Warning Letter’ of May 7, 2014 from the USFDA to Sun Pharmaceuticals &#8211; the no.1 pharma major by market capitalization in India has nailed its Karkhadi, Vadodara, Gujarat based plant in India for similar data deletions as found at &#8230; <a href="http://www.tapanray.in/is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Takeover Magician To Tango Again On A Bold New ‘Sunny’ Tune</title>
		<link>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune</link>
		<comments>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/#comments</comments>
		<pubDate>Mon, 14 Apr 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Dilip]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[magician]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Shanghvi]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[sunny]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[takeover]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wand]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5240</guid>
		<description><![CDATA[The consolidation process of the Indian pharmaceutical industry continues in its own pace. Most recently, the homegrown pharma takeover magician is all set to tango yet again with a bold ‘Sunny’ tune. The low profile creator of high value ‘Sun &#8230; <a href="http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
